NEWS

We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis...

We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and...

Administrator and Finance Coordinator We are looking to appoint a new and key role in our brand new purpose built facilities in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus. This is an exciting and challenging opportunity for a motivated...

The Milner Therapeutics Symposium 2019 is part of Cambridge Biotech Week (25-28th June), a festival of events focused on accelerating scientific ideas and facilitating investment and growth for both early and mature companies on the cutting-edge of healthcare and life...

This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.

Registration for the Milner Therapeutics Symposium on June 25th 2019 is now open! This Symposium is an opportunity for scientists from academia and industry to discuss their latest research and its potential to be applied in pharma and biotech towards new treatments....

Our Annual Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and clinical research and how it could be applied in the pharma and biotech industry to develop new treatments. It is our key networking event for Milner...

  Computational Biology Programme Lead Namshik Han was on the panel at #Impact18 earlier this month, discussing how artificial intelligence is reshaping biotechnology and healthcare sectors. You can listen to Namshik's ideas around AI in healthcare research,...

SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd,...